China NMPA GMP 2026: Navigating Post-Implementation Compliance and Inspections
From Medical Device Global Market Access · 04:45
Show by Pure Global
As of November 1, 2026, China's revised Good Manufacturing Practice (GMP) for medical devices is in full effect, replacing the 2014 version. This episode explains the immediate consequences for manufacturers, as the transition period is now over. We break down the stricter quality management system requirements from NMPA Announcement No. 107 of 2025 and discuss what NMPA inspectors will now be looking for during audits, based on the simultaneously effective 'Guidelines for Inspection of Good Manufacturing Practice.' Learn the practical steps your regulatory and quality teams must take now to ensure continued market access and avoid non-compliance penalties. Key Questions: - What are the most significant changes in China's new GMP versus the previous 2014 version? - How does the new regulation impact design controls, supplier management, and risk management? - With the transition period over, what are the immediate risks for non-compliant manufacturers? - What specific evidence will NMPA inspectors look for under the new inspection guidelines? - Are there different requirements for domestic versus foreign manufacturers? - What are the penalties for failing a GMP inspection under the new rules? - What practical steps can be taken right now to verify and ensure full compliance? Sources: - https://www.emergobyul.com/news/china-nmpa-quality-management-system-qms-legislation-take-effect-november-1-2026 - https://www.dqs-med.com/en/news/chinas-new-medical-device-gmp-in-force-from-1-nov-2026 - https://cisema.com/en/cisema-news/china-nmpa-issues-new-medical-device-gmp-inspection-guidelines/ - https://www.easymedicaldevice.com/news/medical-device-regulatory-update-november-2026/ - https://english.nmpa.gov.cn/2026-11/04/c_930869.htm How Pure Global can help: Pure Global provides end-to-end regulatory solutions to help MedTech companies navigate complex markets like China. Our local experts can conduct a comprehensive gap analysis of your QMS against the new NMPA GMP and inspection guidelines, develop a remediation plan, and assist in updating your technical documentation. With in-country representation, we act as your local contact for NMPA communications and inspection support, ensuring you maintain compliance and market presence. Our AI-powered tools streamline dossier preparation and regulatory intelligence, accelerating your path to market. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.
More episodes of Medical Device Global Market Access
More episodes
- UK Medical Device Registration Guidance: Managing DORS and EUDAMED Pathways
- SFDA Recognized Standards for Medical Devices: Navigating MDS-G020 Requirements
- FDA IVD Emerging Pathogens Guidance: Validation for Section 564 Emergencies
- EU Harmonised Standards Update (November 2026): What MDR & IVDR Manufacturers Must Do Now
- China NMPA Medical Device GMP: Compliance for the November 1, 2026 Changes
- Mexico COFEPRIS Extends Medical Device Registration Renewals to 10 Years
- EU MDCG 2026-4 Rev. 1: Manufacturers Now Responsible for EUDAMED SSCP Uploads
- EU EUDAMED Device Registration Deadline: November 2026 Requirements for MDR and IVDR
- South Korea MFDS Proposes WHO Reliance for IVD Approvals
- UK MHRA Annual Fee Deadline: Urgent Action Required by November 6, 2026
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.